Paris-based investment firm NextStage AM has acquired a minority stake in Evoluderm, the French health and beauty brand founded in 2004 by Nathalie and Gabriel Aiach. The EUR 27 million growth capital investment will support Evoluderm’s next phase of accelerated growth.
Over the past five years, Evoluderm has established itself as a leading health and beauty brand in mass retail. Now distributed in more than 100 countries, the brand has seen its revenue triple in the last three years, reaching nearly EUR 40 million in 2025.
Thanks to the selective integration of its value chain (R&D laboratory, product range development expertise, logistics capabilities, and digital deployment), the brand combines unique agility with the market power of an established player. This allows Evoluderm to launch more than 30 innovations each year and distribute over 20 million products across a comprehensive range of 250 face, body, and hair care items. According to Kantar, Evoluderm ranks among the market’s top performers in customer acquisition.
Evoluderm will use the investment to pursue an ambitious growth plan centered on expanding its physical and digital footprint in France and abroad, strengthening its “cult” brand status by deepening emotional engagement with consumers, and driving continuous innovation to enhance product quality while preserving affordability.
"Evoluderm’s potential lies in a clear and differentiating promise: delivering quality at an accessible price. (…) In a market increasingly polarized between sophisticated usage and budget constraints, Evoluderm offers a third way: accessible and responsible quality. We strongly believe in Evoluderm’s growth potential in the increasingly large ‘mass premium’ market,” said Michaël Strauss-Kahn, Partner at NextStage AM.
